NCT00895102

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.

Conditions

• HCV Infection

Interventions

Type	Name	Description
DRUG	ABT-333 Tablet	See Arm Description for more information.
DRUG	Placebo	See Arm Description for more information.
DRUG	ABT-333 Capsule	See arm description for more information

Timeline

• Start date: 2009-04-01
• Primary completion: 2009-06-01
• First posted: 2009-05-08
• Last updated: 2010-10-13

Locations

1 site across 1 country: United States